Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer

Overview

Journal Noncoding RNA

Date 2022 Jan 25

PMID 35076579

Authors

Silvia Di Agostino

Mahrou Vahabi

Chiara Turco

Giulia Fontemaggi

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast carcinoma characterized by poor prognosis and high rate of metastasis. Current treatment is based on chemo- and/or radiotherapy and surgery. TNBC is devoid of estrogen, progesterone and HER2 receptors. Although precision medicine has come a long way to ameliorate breast cancer disease management, targeted therapies for the treatment of TNBC patients are still limited. Mounting evidence has shown that non-coding RNAs (ncRNAs) drive many oncogenic processes at the basis of increased proliferation, invasion and angiogenesis in TNBC, strongly contributing to tumor progression and resistance to treatments. Many of these ncRNAs are secreted in the tumor microenvironment (TME) and impinge on the activity of the diverse immune and stromal cell types infiltrating the TME. Importantly, secreted ncRNAs may be detected as circulating molecules in serum/plasma from cancer patients and are emerging a promising diagnostic/therapeutic tools in TNBC. This review aims to discuss novel insights about the role of secreted circulating ncRNAs in the intercellular communication in the tumor microenvironment and their potential clinical use as diagnostic and prognostic non-invasive biomarkers in TNBC.

Citing Articles

Detection of Circulating Tumor Cells in the Prognostic Significance of Patients With Breast Cancer: A Retrospective Study.

Xu W, Yuan F J Clin Lab Anal. 2024; 39(1):e25126.

PMID: 39692703 PMC: 11737110. DOI: 10.1002/jcla.25126.

Exploiting Long Non-Coding RNAs and Circular RNAs as Pharmacological Targets in Triple-Negative Breast Cancer Treatment.

Palcau A, Brandi R, Mehterov N, Botti C, Blandino G, Pulito C Cancers (Basel). 2023; 15(16).

PMID: 37627209 PMC: 10453179. DOI: 10.3390/cancers15164181.

RNA-Based Liquid Biopsy in Head and Neck Cancer.

Kabzinski J, Kucharska-Lusina A, Majsterek I Cells. 2023; 12(14).

PMID: 37508579 PMC: 10377854. DOI: 10.3390/cells12141916.

Crosstalk between Noncoding RNAs and the Epigenetics Machinery in Pediatric Tumors and Their Microenvironment.

Pathania A Cancers (Basel). 2023; 15(10).

PMID: 37345170 PMC: 10216492. DOI: 10.3390/cancers15102833.

Non-coding RNA's prevalence as biomarkers for prognostic, diagnostic, and clinical utility in breast cancer.

Ali R, Laskar S, Khan N, Wahab S, Khalid M Funct Integr Genomics. 2023; 23(2):195.

PMID: 37270446 DOI: 10.1007/s10142-023-01123-y.

References

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Amodio N, Raimondi L, Juli G, Stamato M, Caracciolo D, Tagliaferri P . MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol. 2018; 11(1):63. PMC: 5941496. DOI: 10.1186/s13045-018-0606-4. View

Chen T, Wang X, Li C, Zhang H, Liu Y, Han D . CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation. Oncogene. 2021; 40(15):2756-2771. DOI: 10.1038/s41388-021-01739-z. View

Hamam R, Hamam D, Alsaleh K, Kassem M, Zaher W, Alfayez M . Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis. 2017; 8(9):e3045. PMC: 5636984. DOI: 10.1038/cddis.2017.440. View

Tang G, Tang X, Mendu V, Tang X, Jia X, Chen Q . The art of microRNA: various strategies leading to gene silencing via an ancient pathway. Biochim Biophys Acta. 2008; 1779(11):655-62. DOI: 10.1016/j.bbagrm.2008.06.006. View

Takahashi R, Prieto-Vila M, Kohama I, Ochiya T . Development of miRNA-based therapeutic approaches for cancer patients. Cancer Sci. 2019; 110(4):1140-1147. PMC: 6447849. DOI: 10.1111/cas.13965. View

Chu M, Fang Y, Jin Y . CircRNAs as promising biomarker in diagnosis of breast cancer: An updated meta-analysis. J Clin Lab Anal. 2021; 35(9):e23934. PMC: 8418489. DOI: 10.1002/jcla.23934. View

Hanna J, Hossain G, Kocerha J . The Potential for microRNA Therapeutics and Clinical Research. Front Genet. 2019; 10:478. PMC: 6532434. DOI: 10.3389/fgene.2019.00478. View

Nedeljkovic M, Damjanovic A . Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019; 8(9). PMC: 6770896. DOI: 10.3390/cells8090957. View

10.

Dong R, Ma X, Chen L, Yang L . Increased complexity of circRNA expression during species evolution. RNA Biol. 2016; 14(8):1064-1074. PMC: 5680680. DOI: 10.1080/15476286.2016.1269999. View

11.

Zhang M, Liu W, Li W . Imbalance of Molecular Module of TINCR-miR-761 Promotes the Metastatic Potential of Early Triple Negative Breast Cancer and Partially Offsets the Anti-Tumor Activity of Luteolin. Cancer Manag Res. 2021; 13:1877-1886. PMC: 7914057. DOI: 10.2147/CMAR.S288271. View

12.

Chen F, Chen J, Yang L, Liu J, Zhang X, Zhang Y . Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019; 21(4):498-510. DOI: 10.1038/s41556-019-0299-0. View

13.

Tellez-Gabriel M, Knutsen E, Perander M . Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. Int J Mol Sci. 2020; 21(24). PMC: 7763984. DOI: 10.3390/ijms21249457. View

14.

Shaath H, Vishnubalaji R, Elango R, Khattak S, Alajez N . Single-cell long noncoding RNA (lncRNA) transcriptome implicates MALAT1 in triple-negative breast cancer (TNBC) resistance to neoadjuvant chemotherapy. Cell Death Discov. 2021; 7(1):23. PMC: 7835365. DOI: 10.1038/s41420-020-00383-y. View

15.

Fu B, Liu W, Zhu C, Li P, Wang L, Pan L . Circular RNA circBCBM1 promotes breast cancer brain metastasis by modulating miR-125a/BRD4 axis. Int J Biol Sci. 2021; 17(12):3104-3117. PMC: 8375234. DOI: 10.7150/ijbs.58916. View

16.

Li Z, Chen Z, Hu G, Jiang Y . Roles of circular RNA in breast cancer: present and future. Am J Transl Res. 2019; 11(7):3945-3954. PMC: 6684920. View

17.

Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui R . Circulating MicroRNAs in Cancer: Potential and Challenge. Front Genet. 2019; 10:626. PMC: 6656856. DOI: 10.3389/fgene.2019.00626. View

18.

Pardini B, Sabo A, Birolo G, Calin G . Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies. Cancers (Basel). 2019; 11(8). PMC: 6721601. DOI: 10.3390/cancers11081170. View

19.

Yadav P, Mirza M, Nandi K, Jain S, Kaza R, Khurana N . Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients. Tumour Biol. 2016; 37(11):15275-15282. DOI: 10.1007/s13277-016-5361-y. View

20.

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View